中医药防治PCI术后心绞痛的临床研究证据图分析OA
Evidence Mapping Analysis of Clinical Studies on Traditional Chinese Medicine for Prevention and Treatment of Angina Pectoris After PCI
目的 通过证据图谱分析方法,梳理并分析近20年中医药防治经皮冠状动脉介入术(PCI)后心绞痛的相关临床研究,了解其证据分布特征,挖掘潜在优势研究方向,为后续高质量研究提供指导.方法 依托CNKI、WanFang、PubMed等8个中英文数据库,检索2004年1月至2024年9月中医药防治PCI术后心绞痛的相关文献,并通过手工检索以补充灰色文献.逐级筛选后,收集文献相关数据,并采用Cochrane ROB 2.0、AMSTAR量表等工具进行方法学质量评价.结果 本研究共计纳入340篇文献,分析发现近几年整体发文量呈现上升趋势,但现有研究以RCT为主、规模较小、疗程较短.中成药涉及31种,中药汤剂涉及14种,研究较多的分别为通心络胶囊、血府逐瘀汤;结局指标多采用西医指标,未能充分地体现中医特色;随机对照试验、系统评价、Meta分析、临床实践指南及专家共识等文献质量较低,难以较好地提供证据支持.结论 中医药防治PCI术后心绞痛具有独特的中医优势,但高质量循证证据较少,未来研究应更加重视中医药理论在PCI术后心绞痛防治中的应用,并开展更多大样本、多中心的临床研究,以提高临床证据的可靠性与有效性,为未来中医药的发展提供精准的数据支持.
Objective:To sort out and analyze relevant clinical studies on traditional Chinese medicine(TCM)for the prevention and treatment of angina pectoris after percutaneous coronary intervention(PCI)in the past 20 years by means of evidence mapping analysis,clarify the distribution characteristics of evidence,explore potential advantageous research directions,and provide guidance for subsequent high-quality research.Methods:Based on 8 Chinese and English databases including CNKI,WanFang and PubMed,relevant literatures on TCM for preven-tion and treatment of angina pectoris after PCI from January 2004 to September 2024 were retrieved,and gray liter-atures were supplemented by manual retrieval.After stepwise screening,data related to the literatures were collect-ed,and methodological quality evaluation was performed using tools such as Cochrane ROB 2.0 and AMSTAR scale.Results:A total of 340 literatures were included in this study.Analysis showed that the overall number of publications had an upward trend in recent years,but existing studies were mainly randomized controlled trials(RCTs)with small sample sizes and short courses of treatment.A total of 31 kinds of Chinese patent medicines and 14 kinds of Chinese herbal decoctions were involved,among which Tongxinluo Capsules and Xuefu Zhuyu Decoction were the most studied.Outcome measures mostly adopted western medicine indicators,which failed to fully reflect TCM characteristics.The quality of literatures such as RCTs,systematic reviews/meta-analyses,guide-lines and expert consensus was relatively low,making it difficult to provide sufficient evidence support.Conclu-sion:TCM has unique advantages in the prevention and treatment of angina pectoris after PCI,but high-quality evidence-based evidence is scarce.Future research should pay more attention to the application of TCM theory in the prevention and treatment of angina pectoris after PCI,and carry out more large-sample and multicenter clini-cal studies to improve the reliability and effectiveness of clinical evidence,so as to provide accurate data support for the development of TCM in the future.
龚腾皓;潘静鸿;邢作英;司春婴;邱伯雍;樊根豪;宋艳坤;王永霞
河南中医药大学第一附属医院心脏中心/国家区域(中医)心血管诊疗中心,河南郑州 450000||河南中医药大学,河南郑州 450000河南中医药大学,河南郑州 450000河南中医药大学第一附属医院心脏中心/国家区域(中医)心血管诊疗中心,河南郑州 450000||中西医防治重大疾病河南省协同创新中心,河南 郑州 450000河南中医药大学第一附属医院心脏中心/国家区域(中医)心血管诊疗中心,河南郑州 450000||中西医防治重大疾病河南省协同创新中心,河南 郑州 450000河南中医药大学第一附属医院心脏中心/国家区域(中医)心血管诊疗中心,河南郑州 450000||中西医防治重大疾病河南省协同创新中心,河南 郑州 450000河南中医药大学第一附属医院心脏中心/国家区域(中医)心血管诊疗中心,河南郑州 450000||中西医防治重大疾病河南省协同创新中心,河南 郑州 450000河南中医药大学第一附属医院心脏中心/国家区域(中医)心血管诊疗中心,河南郑州 450000||中西医防治重大疾病河南省协同创新中心,河南 郑州 450000河南中医药大学第一附属医院心脏中心/国家区域(中医)心血管诊疗中心,河南郑州 450000||中西医防治重大疾病河南省协同创新中心,河南 郑州 450000
医药卫生
经皮冠状动脉介入术再发心绞痛中医药临床研究证据图分析
Percutaneous coronary interventionRecurrent angina pectorisTraditional Chinese medicineClini-cal studyEvidence mapping analysis
《中国中医急症》 2026 (1)
12-18,7
国家科技重大专项(2023ZD0505703)第五批全国中医临床优秀人才研修项目(国中医药人教函[2022]1号)中原科技创新领军人才项目(244200510002)河南省科技研发计划联合基金(优势学科培育类)项目(232301420021、242301420108)河南省科技攻关项目(242102310087,252102310027)河南省自然科学基金(232300420273,242300420109)河南省中医药科学研究专项课题(2024ZY3021,2024ZY3030)
评论